Cyclacel Pharmaceuticals Stock Up 34.6% In Massive After-Hours Rally
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 05 2025
0mins
Source: Benzinga
Stock Surge: Cyclacel Pharmaceuticals Inc. (CYCC) saw a 34.56% increase in its stock price during after-hours trading, reaching $13.20, following the announcement of promising preclinical data for biliary tract cancer treatment.
Research Findings: The study indicated that biliary tract cancer cells are sensitive to plogosertib, a PLK1 inhibitor, and suggested BUBR1 as a potential biomarker for assessing treatment effectiveness, highlighting a new strategy for BTC therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
